Literature DB >> 10212042

Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study.

B G Stegmayr1, G Almroth, G Berlin, I Fehrman, J Kurkus, R Norda, R Olander, G Sterner, H Thysell, B Wikström, J E Wirén.   

Abstract

A therapeutic removal of antibodies may be achieved by immunoadsorption (IA) or by plasma exchange (PE). The aim of this prospective randomised study was to compare the efficacy of these different techniques with regard to treatment of patients with rapidly progressive glomerulonephritis (RPG) having at least 50% crescents. Forty-four patients with a RPG were included for treatment either by IA or PE (with albumin as substitution for removed plasma). All patients were additionally treated with immunosuppression. A median of 6 sessions of PEs were performed in 23 patients compared with 6 IAs in 21 patients. Goodpasture's syndrome (GP) was present in 6 patients (PE 3, IA 3). All of them started and ended in dialysis, two died. Among the remaining 38 patients (26 men, 12 women) 87% had antibodies to ANCA. Creatinine clearance for PE versus IA were at a median at start 17.1 and 19.8 ml/min, and at 6 months 49 and 49 ml/min, respectively. At 6 months 7 of 10 patients did not need dialysis (remaining: IA 0/5 and PE 2/5, n.s.). The extent of improvement did not differ between the groups. Three patients died during the observation period of 6 months (IA 2; PE 1, on HD). Although no difference was found between the IA or the PE group this study shows that the protocol used was associated with an improved renal function in most patients (except for Goodpasture's syndrome) whereas 70% of them could leave the dialysis program.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10212042

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  7 in total

Review 1.  High-flux versus low-flux membranes for end-stage kidney disease.

Authors:  Suetonia C Palmer; Kannaiyan S Rabindranath; Jonathan C Craig; Paul J Roderick; Francesco Locatelli; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

2.  Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study.

Authors:  Fredrik Uhlin; Wladimir Szpirt; Andreas Kronbichler; Annette Bruchfeld; Inga Soveri; Lionel Rostaing; Eric Daugas; Arnaud Lionet; Nassim Kamar; Cédric Rafat; Marek Mysliveček; Vladimír Tesař; Anders Fernström; Christian Kjellman; Charlotte Elfving; Stephen McAdoo; Johan Mölne; Ingeborg Bajema; Elisabeth Sonesson; Mårten Segelmark
Journal:  J Am Soc Nephrol       Date:  2022-03-08       Impact factor: 14.978

Review 3.  Interventions for renal vasculitis in adults. A systematic review.

Authors:  Giles D Walters; Narelle S Willis; Jonathan C Craig
Journal:  BMC Nephrol       Date:  2010-06-24       Impact factor: 2.388

4.  Interventions for renal vasculitis in adults.

Authors:  Giles D Walters; Narelle S Willis; Tess E Cooper; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2020-01-13

5.  Chapter 14: Anti-glomerular basement membrane antibody glomerulonephritis.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-06

6.  Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis.

Authors:  Yi-yan Zhang; Zheng Tang; Dong-mei Chen; De-hua Gong; Da-xi Ji; Zhi-hong Liu
Journal:  BMC Nephrol       Date:  2014-08-03       Impact factor: 2.388

7.  Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption.

Authors:  Peter Biesenbach; Renate Kain; Kurt Derfler; Thomas Perkmann; Afschin Soleiman; Alexandra Benharkou; Wilfred Druml; Andrew Rees; Marcus D Säemann
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.